TLC518
Type‑2 diabetes (once‑monthly GLP‑1)
Phase 2/3Active
Key Facts
Indication
Type‑2 diabetes (once‑monthly GLP‑1)
Phase
Phase 2/3
Status
Active
Company
About Taiwan Liposome Company
Taiwanese biotech leveraging next‑gen lipid delivery for pain, metabolic and cell‑therapy medicines.
View full company profile